Dr. Chi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-4386Fax+1 617-632-4897- Is this information wrong?
Summary
- Dr. Susan Chi is a highly-qualified healthcare professional based in Boston, MA specializing in Pediatric Hematology & Oncology, with a subspecialty of Pediatric Neuro-Oncology. She initially trained in Pediatrics at Yale-New Haven Medical Center, then pursued fellowships in Pediatric Hematology/Oncology at Memeorial Sloan-Kettering Cancer Center/NY Presbyterian Cornell and Pediatric Neuro-Oncology at NYU. Since 2003, Dr. Chi has been practicing Pediatric Neuro-Oncology at the Dana-Farber Cancer Institute/Boston Children's Hospital. She has been involved in numerous experimental clinical trials and has a distinguished record of publications, including pivotal work on Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare infant brain tumors. She has also contributed to the development of innovative treatments and to the establishment of new standards-of-care through the clinical trials she has led.
Education & Training
- NYU Grossman School of MedicineFellowship, Pediatric Neuro-Oncology, 2001 - 2002
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1998 - 2001
- Yale-New Haven Medical CenterChief Residency, Pediatrics, 1997 - 1998
- Yale-New Haven Medical CenterResidency, Pediatrics, 1994 - 1997
- Icahn School of Medicine at Mount SinaiClass of 1994
- Princeton UniversityBA, 1990
Certifications & Licensure
- RI State Medical License 2022 - 2026
- MA State Medical License 2003 - 2025
- NH State Medical License 2023 - 2025
- CT State Medical License 1997 - 2024
- ME State Medical License 2023 - 2024
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Start of enrollment: 2018 Sep 24
Roles: Contact
- Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Roles: Contact, Principal Investigator
- Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy Start of enrollment: 2020 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 341 citationsMechanisms and therapeutic implications of hypermutation in gliomas.Mehdi Touat, Yvonne Y. Li, Adam Boynton, Liam F. Spurr, J. Bryan Iorgulescu
Nature. 2020-04-15 - 144 citationsLack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium StudySridharan Gururangan, Susan N. Chi, Tina Young Poussaint, Arzu Onar-Thomas, Richard J. Gilbertson
Journal of Clinical Oncology. 2010-06-20 - 238 citationsGenome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine GliomaBarbara S. Paugh, Alberto Broniscer, Chunxu Qu, Claudia P. Miller, Junyuan Zhang
Journal of Clinical Oncology. 2011-10-20
Press Mentions
- EZH2 Inhibitor Shows Promise Among Children with Certain Solid TumorsFebruary 20th, 2018
- What ‘Beans’ Taught Her Parents About Pediatric Cancer, the Need for Research, and Patient AdvocacyMarch 23rd, 2021
Professional Memberships
- Member
Hospital Affiliations
- Boston Children's HospitalBoston, Massachusetts
- Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: